Literature DB >> 28129018

Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review.

Michael H Woodworth1, Cynthia Carpentieri1, Kaitlin L Sitchenko1, Colleen S Kraft1,2.   

Abstract

Fecal microbiota transplantation is best understood as an effective and inexpensive therapy for recurrent Clostridium difficile infection but fecal donor selection and screening should be periodically revised. Here, we review current recommendations for selection and screening of fecal donors for fecal microbiota transplantation. We recommend considering diabetes mellitus, prior cardiovascular events, and clinical healthcare exposure as fecal donor exclusion criteria until more is known about the association of these conditions with the human gut microbiome. We review the non-bacterial members of the human gut microbiome, associations of the gut microbiome with colorectal malignancies, the human gut resistome and how these may impact future donor screening recommendations. Collaboration between clinicians, clinical laboratory scientists, industry and regulatory agencies will be critically important for continued improvement in donor selection and screening.

Entities:  

Keywords:  Clostridium difficile; FMT; antibiotic resistance; fecal microbiota transplantation; gut microbial therapeutics; microbiome; resistome; stool donor screening

Mesh:

Year:  2017        PMID: 28129018      PMCID: PMC5479407          DOI: 10.1080/19490976.2017.1286006

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  62 in total

1.  Ensuring the safe and effective FDA regulation of fecal microbiota transplantation.

Authors:  Rachel E Sachs; Carolyn A Edelstein
Journal:  J Law Biosci       Date:  2015-07-06

2.  Disease-specific alterations in the enteric virome in inflammatory bowel disease.

Authors:  Jason M Norman; Scott A Handley; Megan T Baldridge; Lindsay Droit; Catherine Y Liu; Brian C Keller; Amal Kambal; Cynthia L Monaco; Guoyan Zhao; Phillip Fleshner; Thaddeus S Stappenbeck; Dermot P B McGovern; Ali Keshavarzian; Ece A Mutlu; Jenny Sauk; Dirk Gevers; Ramnik J Xavier; David Wang; Miles Parkes; Herbert W Virgin
Journal:  Cell       Date:  2015-01-22       Impact factor: 41.582

3.  Microbiota organization is a distinct feature of proximal colorectal cancers.

Authors:  Christine M Dejea; Elizabeth C Wick; Elizabeth M Hechenbleikner; James R White; Jessica L Mark Welch; Blair J Rossetti; Scott N Peterson; Erik C Snesrud; Gary G Borisy; Mark Lazarev; Ellen Stein; Jamuna Vadivelu; April C Roslani; Ausuma A Malik; Jane W Wanyiri; Khean L Goh; Iyadorai Thevambiga; Kai Fu; Fengyi Wan; Nicolas Llosa; Franck Housseau; Katharine Romans; XinQun Wu; Florencia M McAllister; Shaoguang Wu; Bert Vogelstein; Kenneth W Kinzler; Drew M Pardoll; Cynthia L Sears
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-08       Impact factor: 11.205

4.  Healthy human gut phageome.

Authors:  Pilar Manrique; Benjamin Bolduc; Seth T Walk; John van der Oost; Willem M de Vos; Mark J Young
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-29       Impact factor: 11.205

5.  The human gut microbiome as a screening tool for colorectal cancer.

Authors:  Joseph P Zackular; Mary A M Rogers; Mack T Ruffin; Patrick D Schloss
Journal:  Cancer Prev Res (Phila)       Date:  2014-08-07

Review 6.  Blastocystis in Health and Disease: Are We Moving from a Clinical to a Public Health Perspective?

Authors:  Lee O'Brien Andersen; Christen Rune Stensvold
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

7.  Comparison of brush and biopsy sampling methods of the ileal pouch for assessment of mucosa-associated microbiota of human subjects.

Authors:  Susan M Huse; Vincent B Young; Hilary G Morrison; Dionysios A Antonopoulos; John Kwon; Sushila Dalal; Rose Arrieta; Nathaniel A Hubert; Lici Shen; Joseph H Vineis; Jason C Koval; Mitchell L Sogin; Eugene B Chang; Laura E Raffals
Journal:  Microbiome       Date:  2014-02-14       Impact factor: 14.650

Review 8.  The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation.

Authors:  Amy Langdon; Nathan Crook; Gautam Dantas
Journal:  Genome Med       Date:  2016-04-13       Impact factor: 11.117

9.  How next-generation sequencing and multiscale data analysis will transform infectious disease management.

Authors:  Theodore R Pak; Andrew Kasarskis
Journal:  Clin Infect Dis       Date:  2015-08-06       Impact factor: 9.079

Review 10.  Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications.

Authors:  Luis Furuya-Kanamori; John Marquess; Laith Yakob; Thomas V Riley; David L Paterson; Niki F Foster; Charlotte A Huber; Archie C A Clements
Journal:  BMC Infect Dis       Date:  2015-11-14       Impact factor: 3.090

View more
  26 in total

1.  Evolving Strategies to Manage Clostridium difficile Colitis.

Authors:  Jessica A Bowman; Garth H Utter
Journal:  J Gastrointest Surg       Date:  2019-11-25       Impact factor: 3.452

2.  Fecal microbiota transplantation-early steps on a long journey ahead.

Authors:  Alexander Khoruts
Journal:  Gut Microbes       Date:  2017-04-10

3.  Ethical Considerations in Microbial Therapeutic Clinical Trials.

Authors:  Michael H Woodworth; Kaitlin L Sitchenko; Cynthia Carpentieri; Rachel J Friedman-Moraco; Tiffany Wang; Colleen S Kraft
Journal:  New Bioeth       Date:  2017-10-17

Review 4.  Orchestrating the fecal microbiota transplantation: Current technological advancements and potential biomedical application.

Authors:  Manisha Nigam; Abhaya Shikhar Panwar; Rahul Kunwar Singh
Journal:  Front Med Technol       Date:  2022-09-22

Review 5.  Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives.

Authors:  Lie Zheng; Yong-Yi Ji; Xin-Li Wen; Sheng-Lei Duan
Journal:  World J Gastroenterol       Date:  2022-06-21       Impact factor: 5.374

Review 6.  Gut Microbiota: Influence on Carcinogenesis and Modulation Strategies by Drug Delivery Systems to Improve Cancer Therapy.

Authors:  Runqi Zhu; Tianqun Lang; Wenlu Yan; Xiao Zhu; Xin Huang; Qi Yin; Yaping Li
Journal:  Adv Sci (Weinh)       Date:  2021-03-09       Impact factor: 16.806

Review 7.  Sequence meets function-microbiota and cardiovascular disease.

Authors:  Myungsuk Kim; Md Nazmul Huda; Brian J Bennett
Journal:  Cardiovasc Res       Date:  2022-01-29       Impact factor: 10.787

Review 8.  Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients.

Authors:  Nirja Mehta; Tiffany Wang; Rachel J Friedman-Moraco; Cynthia Carpentieri; Aneesh K Mehta; Nadine Rouphael; Tanvi Dhere; Christian P Larsen; Colleen S Kraft; Michael H Woodworth
Journal:  J Clin Microbiol       Date:  2021-06-16       Impact factor: 11.677

9.  Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis.

Authors:  Xiao Ding; Qianqian Li; Pan Li; Ting Zhang; Bota Cui; Guozhong Ji; Xiang Lu; Faming Zhang
Journal:  Drug Saf       Date:  2019-07       Impact factor: 5.228

10.  Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence In Vivo.

Authors:  George A Naclerio; Nader S Abutaleb; Daoyi Li; Mohamed N Seleem; Herman O Sintim
Journal:  J Med Chem       Date:  2020-10-06       Impact factor: 8.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.